The TruSite ICE Catheter is the future of cost-effective miniaturized procedural guidance for electrophysiology and structural heart procedures.
MIDDLETOWN, DE, March 02, 2021 /Neptune100/ — SoundCath LLC, an emerging company developing high-resolution real-time 2D and 4D volume intracardiac ultrasound imaging solutions, announced the successful results from its latest preclinical feasibility study. This technology improves current procedures and at a lower cost allowing for broader access in both developed and emerging markets.
“Our initial preclinical experience of the TruSite™ ICE Catheter showed excellent image quality and very good navigation characteristics,” stated Ben Guiot, M.D. director and clinical advisor. “TruSite™ utilizes the latest MEMS transducer imaging technology. This is the future of cost-effective miniaturized procedural guidance for electrophysiology and structural heart procedures.”
About SoundCath LLC
SoundCath LLC is a privately held medical device company focusing on the development and commercialization of advanced, high resolution, miniaturized, cost-effective ultrasound catheter imaging technologies. The company is developing the TruSite ICE Catheter to set forth a new era in transcatheter cardiac interventions through the advancement of 2D and 4D intracardiac echocardiography. Our patented technologies are designed to provide the highest resolution, smallest and most maneuverable ICE solutions at significantly reduced cost compared to currently available products. The TruSite ICE Catheter is currently in the pre-clinical stage and not available for sale. To learn more about SoundCath, please email [email protected].